News
Life-threatening adverse events in liver cancer less frequent with ICI therapy
- Author:
- Jim Kling
While tyrosine kinase inhibitors were found to be associated with more serious adverse events, both treatments had similar toxic effects.
News
Lung cancer treatment combo may be effective after ICI failure
- Author:
- Jim Kling
Phase 2 trial offers hope of a chemotherapy-free option for patients with advanced NSCLC.
News
The shifting sands of lung cancer screening
- Author:
- Jim Kling
Studies find encouraging trends of stage shifting and minority screening, but more work remains.
News
Pembrolizumab for melanoma bittersweet, doctor says
- Author:
- Jim Kling
“Until we can further define who the highest-risk patients are, I think it’s hard to give it to everyone,” one doctor says.
News
New KRAS inhibitor shows promise in NSCLC
- Author:
- Jim Kling
One out of three lung cancer patients previously treated with chemotherapy and immune therapy responded to a new targeted therapy.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Bhan_Irun_Mass_web.jpg)
New insights into worldwide biliary tract cancer incidence, mortality
- Author:
- Jim Kling
Previous studies have examined worldwide BTC incidence; few looked at multiple global regions or at all subtypes.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Rosen_Michael_web.jpg)
IBD study hints at cause of postacute COVID
- Author:
- Jim Kling
Persistent viral antigens could be behind multiorgan symptoms: The majority of patients with gut antigen persistence had symptoms of postacute...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Thiagarajah_Jay_MASS_web.jpg)
Two genetic intestinal diseases linked
- Author:
- Jim Kling
These rare conditions have separate genetic mutations but can share symptoms; new evidence suggests the two mutated proteins work together.
News
ASCO outlines optimal treatments for patients with metastatic clear cell renal cell carcinoma
- Author:
- Jim Kling
A dramatic increase in therapy options prompted the first guidance issued by ASCO earlier this year.
News
First-line nivolumab monotherapy effective in some kidney cancers
- Author:
- Jim Kling
A phase 2 trial found high response rates in patients classified as favorable risk and more widespread PD-L1 expression.
News
Melanoma incidence is up, but death rates are down
- Author:
- Jim Kling
“This is very encouraging data and represents the real-world effectiveness of these therapies.”
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/November-2018/Martin_Paul_MIAMI_web.jpg)
Are pain meds the only option for chronic pain in cirrhosis?
- Author:
- Jim Kling
An emphasis on nonpharmacologic approaches, such as diet and psychological interventions, can sometimes handle even less familiar sources of pain...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/September-2017/GERD_web.jpg)
Baclofen shows limited role in GERD
- Author:
- Jim Kling
The drug showed benefit in PPI refractory symptoms for patients with non-acid reflux.
News
Liver-related telehealth faces tech barriers
- Author:
- Jim Kling
Rural and underserved areas may lack the technology needed to access innovative care solutions.
News
Metastatic lobular, ductal cancers respond similarly
- Author:
- Jim Kling
Lobular cancers differ physiologically, but trial results generally apply to ductal tumors.